

International Application No.: PCT/EP00/02478
Attorney Docket No.: BC45226

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bruck et al.

Docket No.: BC45226

Serial No.: Unknown

Filed: Herewith

For: Novel Compounds

Group Art Unit No.: Unknown

Examiner: Unknown

PRELIMINARY AMENDMENT

Sir:

Please enter this Preliminary Amendment into the record of the above-identified patent application before examination and the calculation of fees.

In the Claims:

Please delete the claims of the application as filed in the PCT and substitute therefor:

38. An isolated polypeptide comprising a member selected from the group consisting of:
- (a) an amino acid sequence which has at least 90% identity to SEQ ID NO:2;
 - (b) an immunogenic fragment of the amino acid sequence of (a), wherein the immunogenic fragment is at least 90% identical to an aligned contiguous segment of SEQ ID NO:2; and
 - (c) an immunogenic fragment of the amino acid sequence of (a) that matches an aligned contiguous segment of SEQ ID NO:2 with no more than five single amino acid substitutions, deletions or additions;

wherein the isolated polypeptide, when administered to a subject in a suitable composition which can include an adjuvant or a suitable carrier coupled to the polypeptide, induces an immune response that recognizes a polypeptide having the sequence of SEQ ID NO:2.

39. The isolated polypeptide of Claim 38 wherein the amino acid sequence has at least 95% identity to SEQ ID NO:2 or the aligned contiguous segment of SEQ ID NO:2.

40. The isolated polypeptide of Claim 39 wherein the polypeptide consists of the amino acid sequence of SEQ ID NO:2.